FDA grants fast track designation to IN10018 for ovarian cancer
The FDA granted fast track designation to IN10018 for treatment of platinum-resistant ovarian cancer.
IN10018 (InxMed) is a focal adhesion kinase small molecule inhibitor.
Preclinical and clinical data suggested the agent has promising efficacy when combined with standard chemotherapy for women with platinum-resistant ovarian cancer, according to an InxMed-issued press release.
“[Fast track designation] is an important milestone for InxMed,” Zaiqi Wang, MD, PhD, the company’s chairman and CEO, said in the release. “IN10018 is one of our critical assets to fulfill our ‘best-in-disease combination’ development strategy. We will leverage the advantage of fast track status and work closely with U.S. FDA to speed up further clinical development.”
Read more about